327
Participants
Start Date
January 31, 2013
Primary Completion Date
January 31, 2015
Study Completion Date
April 30, 2016
Pacritinib
Best Available Therapy
CTI Investigational Site 10003, Greenville
CTI Investigational Site 10004, Omaha
CTI Investigational Site 10002, Scottsdale
CTI Investigational Site 10001, Morristown
CTI Investigational Site 61006, Box Hill
CTI Investigational Site 61001, Coffs Harbour
CTI Investigational Site 61005, Geelong
CTI Investigational Site 61003, Gosford
CTI Investigational Site 61004, Hobart
CTI Investigational Site 61002, Milton
CTI Investigational Site 32002, Antwerp
CTI Investigational Site 32003, Antwerp
CTI Investigational Site 32001, Bruges
CTI Investigational Site 32005, Brussels
CTI Investigational Site 32004, La Louvière
CTI Investigational Site 42003, Brno
CTI Investigational Site 42001, Olomouc
CTI Investigational Site 42002, Pilsen
CTI Investigational Site 42004, Prague
CTI Investigational Site 33005, Amiens
CTI Investigational Site 33006, Caen
CTI Investigational Site 33011, Grenoble
CTI Investigational Site 33012, Lens
CTI Investigational Site 33007, Lille
CTI Investigational Site 33001, Nîmes
CTI Investigational Site 33004, Paris
CTI Investigational Site 33008, Paris
CTI Investigational Site 33009, Pessac
CTI Investigational Site 33010, Pierre-Bénite
CTI Investigational Site 33003, Strasbourg
CTI Investigational Site 33002, Toulouse
CTI Investigational Site 49006, Berlin
CTI Investigational Site 49007, Berlin
CTI Investigational Site 49001, Cologne
CTI Investigational Site 49003, Dresden
CTI Investigational Site 49008, Essen
CTI Investigational Site 49002, Freiburg im Breisgau
CTI Investigational Site 49005, Mainz
CTI Investigational Site 49004, München
CTI Investigational Site 49009, Münster
CTI Investigational Site 36002, Budapest
CTI Investigational Site 36005, Debrecen
CTI Investigational Site 36006, Gyula
CTI Investigational Site 36003, Kaposvár
CTI Investigational Site 36004, Kecskemét
CTI Investigational Site 36001, Szeged
CTI Investigational Site 36008, Szolnok
CTI Investigational Site 36007, Szombathely
CTI Investigational Site 39003, Bologna
CTI Investigational Site 39001, Florence
CTI Investigational Site 39005, Milan
CTI Investigational Site 39004, Monza
CTI Investigational Site 39002, Padua
CTI Investigational Site 39008, Reggio Emilia
CTI Investigational Site 39006, Rimini
CTI Investigational Site 31001, Amsterdam
CTI Investigational Site 31002, Maastricht
CTI Investigational Site 31003, Rotterdam
CTI Investigational Site 31004, Utrecht
CTI Investigational Site 64001, Christchurch
CTI Investigational Site 64004, Dunedin
CTI Investigational Site 64002, Hamilton
CTI Investigational Site 64003, Takapuna
CTI Investigational Site 70011, Izhevsk
CTI Investigational Site 70008, Moscow
CTI Investigational Site 70009, Moscow
CTI Investigational Site 70002, Petrozavodsk
CTI Investigational Site 70001, Saint Petersburg
CTI Investigational Site 70004, Saint Petersburg
CTI Investigational Site 70010, Saint Petersburg
CTI Investigational Site 70005, Samara
CTI Investigational Site 70006, Sochi
CTI Investigational Site 70007, Volgograd
CTI Investigational Site 44004, Birmingham
CTI Investigational Site 44008, Bournemouth
CTI Investigational Site 44002, Cambridge
CTI Investigational Site 44003, Cardiff
CTI Investigational Site 44001, London
CTI Investigational Site 44007, London
CTI Investigational Site 44006, Manchester
CTI Investigational Site 44005, Oxford
Lead Sponsor
CTI BioPharma
INDUSTRY